Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04119206
Other study ID # Tolvaptan
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2009
Est. completion date December 31, 2013

Study information

Verified date October 2019
Source University of Erlangen-Nürnberg Medical School
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Context. The relevance of hyponatremia has been acknowledged by guidelines from the United States of America (2013) and Europe (2014). However, treatment recommendations differ due to limited evidence.

Objective. In hyponatremia following pituitary surgery - caused by the syndrome of inappropriate antidiuretic hormone (SIADH) secretion - the investigators compared fluid restriction with the pharmacological increase of water excretion by blocking the vasopressin 2 receptors with tolvaptan at a low and moderate dose.

Design. Prospective observational study.

Setting. Neurosurgical Department of a University hospital with more 200 pituitary procedures per year.

Patients. Participants undergoing surgery for sellar lesions and developing a serum sodium below 135 mmol/L. The diagnosis of SIADH was established by eu- or hypervolemia (daily measurement of body weight and fluid balance daily), an inappropriately concentrated urine (specific gravity) and exclusion of a cortico- and thyreotropic insufficiency.

Intervention. Participants were treated with fluid restriction (n=38) or tolvaptan at 3.75 (n=38) or 7.5 mg (n=48) orally.

Main Outcome Measures. Treatment efficacy was assessed by the duration of hyponatremia, sodium nadir and length of hospitalization. Safety was established by an increment serum sodium below 10 mmol/L per day and exclusion of side effects.


Description:

Patients of the Department of Neurosurgery, University of Erlangen-Nuremberg, undergoing surgery for sellar lesions were prospectively included. The study protocol was approved by the local Ethical Committee (Re.-No. 103_12 BC). Informed written consent was given by the participants or the next-of-kin in each case. Exclusion criteria comprised of those below 18 years of age, pregnancy and a drug intolerance.

Patients Baseline information included age, gender, BMI and the clinical presentation. The pre-operative work-up included an opthalmological examination, a 1.5 Tesla magnetic resonance imaging (MRI) with 2mm axial, coronal and sagittal sections revealing the tumor localization, extension, and its invasive behavior. Microsurgery was always performed by the same surgeon. The macroscopic delineation and invasiveness, the surgical manipulation of the pituitary stalk and extend of tumor resection, surgical complications, as well as an intraoperative cerebrospinal fluid (CSF) leak were documented. The tumor and the dura of the floor of the sella were examined histo-pathologically including the proliferation rate, regressive changes, atypical findings, and the existence of Crooke cells and periodic acid-Schiff (PAS) expression. Routine laboratory work-up included creatinine, urea, and alanine aminotransferase (ALT).

The pre- and postoperative endocrine testing of the pituitary function comprised the basal values of cortisol (CORT), growth hormone (GH), insulin-like growth factor (IGF) 1, thyroid stimulating hormone (TSH), free thyroxine (fT4), total triiodothyronine (tT3), luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone (TES), estradiol (E2), and prolactin (PRL). Insufficiency of the corticotropic axis was determined by a short synacthen test (adreno-corticotropic hormone; ACTH)-test stimulating with 0.25 mg Syntropin (Synacthen, Novartis Pharma, Nuremberg, Germany) intra-venously and serum cortisol measurement at 0 and 30 minutes.

Surveillance Post-operatively, participants were transferred to the general floor. For a minimum of 10 days, fluid intake, body weight, and urine volume with specific gravidity are documented daily, along with blood pressure and heart rate three-times daily, blood samples for the assessment of electrolytes are taken on day 1, 2, 3, 5, 7, and 9. An endocrine dynamic testing was performed on day 7.

Analytical methods Venous blood samples were drawn in the morning between 7:00 and 9:00 am into pre-cooled tubes. Clotted samples were promptly centrifuged at 3,000 X g for 15 min at 4 degree Celsius, and then the plasma was frozen at -80 degree Celsius until analysis.

An automated system (Immulite®2000, Diagnostic Products Corporation) was used for the following serum hormone measurements: Serum cortisol levels > 10.5 µg/dL, with an assay sensitivity of 0.20 µg/dL, was considered normal; a cortisol response peak to the ACTH-test higher than 18 µg/dl was considered adequate; for IGF-1 of 135-485 ng/mL (18-30 years), 120-397 ng/mL (31-40 years), 113-306 ng/mL (41-50 years), 100-250 ng/mL (51-60 years), and 92-229 ng/mL (>60 years) (assay sensitivity of 20 ng/mL); LH > 0.25 U/L (follicular phase) and > 20 U/L (menopausal) in women, and > 1 international units (IU)/L in men (assay sensitivity of 0.05 mIU/mL); FSH > 0.25 U/L (follicular phase) and > 30 U/L (menopausal) in women, and > 1 IU/L in men (assay sensitivity of 0.1 mIU/mL); TES > 90 ng/dL in men (assay sensitivity of 15 ng/dL); E2 > 60 pg/mL (follicular phase) and > 10 pg/mL (menopausal) in women (assay sensitivity of 15 pg/mL); PRL < 500 micro international units (µIU)/L (assay sensitivity of 0.16 µU/L); PRL serum concentrations were considered normal < 360 ng/ml in men and < 530 ng/mL in women. TSH serum concentrations were considered normal > 0.45 µU/mL, fT4 > 0.77 ng/dL, and tT3 > 0.8 ng/mL.

Study design Treatment of hyponatremia was initiated as soon as a SIADH was confirmed by eu- or hypervolemia (daily measurement of body weight and fluid balance), an inappropriately concentrated urine (measurement of specific gravity), and exclusion of a cortico- and thyreotropic insufficiency. The established treatment regime consisted of a restriction of fluid intake < 1 L whenever the serum sodium dropped below 135 mmol/L or the body weight gained more than 1 kg (fluid restriction). In a second cohort of patients, the fluid restriction was replaced by a low dosage of tolvaptan (tolvaptan 3.75 mg), and in a third cohort by a medium dosage (tolvaptan 7.5 mg). Since a rapid correction of hyponatremia is hazardous and leaves the patient vulnerable to the risk of osmotic demyelination, we not only started the cohort study with a very low concentration of 3.75 mg tolvaptan, but also established a tight follow-up regime after medication. The serum sodium concentration was controlled at 6:00 pm. Those participants, whose serum sodium concentration further dropped below 132 mmol/L, were treated with a second tablet of tolvaptan and the serum sodium was measured the next day at 8:00 am. Those participants, whose serum sodium was increased by not more than 5 mmol/L underwent the next blood check on the next day at 8:00 am. Those participants, whose serum sodium increased by more than 5 mmol/L were treated by 1L tea/water or a 500 mL 5% glucose infusion.

Statistical analysis SPSS statistical software (SPSS Inc., Chicago, Illinois, USA) was used for all statistical analyses. Analyses were performed using the Chi-squared test and Mann-Whitney U tests where appropriate. Significance was accepted at p < 0.05.


Recruitment information / eligibility

Status Completed
Enrollment 334
Est. completion date December 31, 2013
Est. primary completion date December 31, 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

Informed written consent was given by the participant or the next-of-kin.

Exclusion Criteria:

Age below 18 years Pregnancy Tolvaptan intolerance.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Erlangen-Nürnberg Medical School

Outcome

Type Measure Description Time frame Safety issue
Primary Mean serum sodium concentration Postoperative mean serum sodium Day 1 post-op up to 15 days
Primary Serum sodium nadir concentration Postoperative serum sodium nadir Day 1 post-op up to 15 days
Primary Number of days with serum sodium concentration below 136mmol/L No. of postoperative days serum sodium was below 136mmol/L Day 1 post-op up to 15 days
Primary Number of days with serum sodium concentration below 133mmol/L No. of postoperative days serum sodium was below 133mmol/L Day 1 post-op up to 15 days
Secondary Number of events with mild serum sodium overcorrection Serum sodium overcorrection > 5mmol/L*24hrs Day 1 post-op up to 15 days
Secondary Number of events with severe serum sodium overcorrection Serum sodium overcorrection > 10mmol/L*24hrs Day 1 post-op up to 15 days
Secondary Number of days in the hospital Duration of hospital stay Up to 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT06037928 - Plasma Sodium and Sodium Administration in the ICU
Recruiting NCT04561531 - Efficacy and Safety of Bolus Comparing With Continuous Drip of 3% NaCl in Patients With Severe Symptomatic Hyponatremia. N/A
Terminated NCT02012959 - Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia Phase 3
Recruiting NCT02936167 - Comparison of Ringer Lactate and Isotonic Acetate Solution as Perioperative Maintenance Fluid for Children N/A
Completed NCT00621348 - Maintenance Intravenous Fluids in Children Phase 3
Terminated NCT03703713 - Colloid Osmotic Pressure and Osmolality in Hyponatremia
Completed NCT02926989 - Intravenous Fluids in Hospitalised Children Phase 4
Terminated NCT02959411 - Tolvaptan for Advanced or Refractory Heart Failure Phase 4
Completed NCT02573077 - An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
Withdrawn NCT02667977 - Reexamining Hypotonic Intravenous Fluid Use N/A
Terminated NCT01708811 - Hyponatremia and Myometrium Contractility. An Invitro Study N/A
Completed NCT01456533 - Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients N/A
Withdrawn NCT01326429 - Frequency and Origin of Dysnatremias in the Emergency Department N/A
Terminated NCT01227512 - Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia Phase 3
Recruiting NCT06013800 - Hyponatremia Volume Status Analysis by Point-of-care Ultrasound
Terminated NCT04020926 - Impact of Hyponatremia on Muscle Strength, Gait and Cognitive Function
Completed NCT02545101 - An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH N/A
Withdrawn NCT02442674 - A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia Phase 3
Terminated NCT02215148 - Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients N/A
Recruiting NCT01748331 - The Effect of Fluid Restriction in Congestive Heart Failure Complicated With Hyponatremia N/A